Research Article Órpez-Zafra, Pavía, Pinto-Medel et al.
5 Uzé G, Lutfalla G, Bandu MT et al. Behavior of a cloned murine interferon alpha/beta receptor expressed in homospecific or heterospecific background. Proc. Natl Acad. Sci. USA 89(10), 4774–4778 (1992).
6 Cutrone EC, Langer JA. Contributions of cloned type I interferon receptor subunits to differential ligand binding. FEBS Lett. 404(2–3), 197–202 (1997).
7
Pestka S, Langer JA, Zoon KC et al. Interferons and their actions. Annu. Rev. Biochem. 56, 727–777 (1987).
8 Baron S, Tyring SK, Fleischmann WRJ et al. The interferons. Mechanisms of action and clinical applications. JAMA 266(10), 1375–1383 (1991).
9 Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem. J. 300(Pt 2), 281–290 (1994).
10 Fernandez-Botran R, Chilton PM, Ma Y. Soluble cytokine receptors: their roles in immunoregulation, disease, and therapy. Adv. Immunol. 63, 269–336 (1996).
11 Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin. Invest. Drugs 9(3), 497–514 (2000).
12 Domanski P, Witte M, Kellum M et al. Cloning and expression of a long form of the beta subunit of the interferon alpha beta receptor that is required for signaling. J. Biol. Chem. 270(37), 21606–21611 (1995).
13 Novick D, Cohen B, Tal N et al. Soluble and membrane- anchored forms of the human IFN-alpha/beta receptor. J. Leukoc. Biol. 57(5), 712–718 (1995).
14 Novick D, Cohen B, Rubinstein M. Soluble interferon-alpha receptor molecules are present in body fluids. FEBS Lett. 14(3), 445–448 (1992).
15 Peleg-Shulman T, Roisman LC, Zupkovitz G et al. Optimizing the binding affinity of a carrier protein: a case study on the interaction between soluble ifnar2 and interferon beta. J. Biol. Chem. 279(17), 18046–18053 (2004).
16 McKenna SD, Vergilis K, Arulanandam AR et al. Formation of human IFN-beta complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice. J. Interferon Cytokine Res. 24(2), 119–129 (2004).
17 Hardy MP, Owczarek CM, Trajanovska S et al. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 97(2), 473–482 (2001).
18 Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69(2), 292–302 (2011).
19
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for
Human Use (ICH) (2005) Validation of analytical procedures: text and methodology Q2(R1).
www.ich.org
20 Lee JW, Devanarayan V, Barrett YC et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 23(2), 312–328 (2006).
21 Valentin MA, Ma S, Zhao A et al. Validation of immunoassay for protein biomarkers: bioanalytical study plan implementation to support pre-clinical and clinical studies. J. Pharm. Biomed. Anal. 55(5), 869–877 (2011).
22 Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(13), 1259–1271 (2009).
23 Mizukoshi E, Kaneko S, Kaji K et al. Serum levels of soluble interferon alfa/beta receptor as an inhibitory factor of interferon in the patients with chronic hepatitis C. Hepatology 30(5), 1325–1331 (1999).
24 Ambrus JL, Ambrus JLJ, Chadha S et al. Mechanism(S) of interferon inhibitory activity in blood from patients with AIDS and patients with lupus erythematosus with vasculitis. Res. Commun. Mol. Pathol. Pharmacol. 96(3), 255–265 (1997).
25 Ambrus JLS, Dembinski W, Ambrus JLJ et al. Free interferon-alpha/beta receptors in the circulation of patients with adenocarcinoma. Cancer 98(12), 2730–2733 (2003).
26 Oppenheim JJ. Cytokines: past, present, and future. Int. J. Hematol. 74(1), 3–8 (2001).
27 Uzé G, Schreiber G, Piehler J et al. The receptor of the type I interferon family. Curr. Top Microbiol. Immunol. 316, 17–95 (2007).
28 Cohen B, Novick D, Barak S et al. Ligand-induced association of the type I interferon receptor components. Mol. Cell Biol. 15(8), 4208–4214 (1995).
29 Novick D, Cohen B, Rubinstein M. The human interferon alpha/beta receptor: characterization and molecular cloning. Cell 77(3), 391–400 (1994).
30 Chadha K, Weinstock-Guttman B, Zivadinov R et al. Interferon inhibitory activity in patients with multiple sclerosis. Arch. Neurol. 63(11), 1579–1584 (2006).
31 Villar LM, Masjuan J, Sadaba MC et al. Early differential diagnosis of multiple sclerosis using a new oligoclonal band test. Arch. Neurol. 62(4), 574–577 (2005).
32 Villar LM, Espińo M, Costa-Frossard L et al. High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. Clin. Chim. Acta 413(23–24), 1813–1816 (2012).
33 Comabella M, Fernández M, Martin R et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 133(Pt 4), 1082–1093 (2010).
2880
Bioanalysis (2015) 7(22)
future science group
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154